—
Table of Contents
1. Introduction
3. What Is the Gut Microbiome and Why Does It Matter for Cancer Patients?
4. The Gut-Immune System Connection: Why Microbiome Health Is Central to Cancer Care
5. How Gut Bacteria Directly Influence Chemotherapy Drug Metabolism and Efficacy
6. Microbiome Diversity and Immunotherapy Response Rates: What the Research Shows
7. How Cancer Treatments Like Antibiotics and Radiation Disrupt the Gut Microbiome
8. Gut Dysbiosis and Treatment Side Effects: From Mucositis to Immunosuppression
9. Fecal Microbiota Transplantation (FMT) as a Strategy to Enhance Cancer Treatment
10. The Role of Diet in Shaping the Gut Microbiome During Cancer Therapy
11. Probiotics, Prebiotics, and Synbiotics: Evidence-Based Use in Oncology Settings
12. Future Directions: Microbiome-Based Biomarkers and Personalized Cancer Treatment
13. Frequently Asked Questions
14. Conclusion
16. Sources
—
Introduction
At Courage Against Cancer (CAC), our mission is to empower cancer patients, survivors, and caregivers with accurate, compassionate, and evidence-informed education — and this deep-dive resource on the gut microbiome and cancer treatment is part of that commitment. The gut microbiome directly affects how cancer patients respond to traditional treatments, including chemotherapy, radiation, and immunotherapy, by influencing drug metabolism, immune activation, and the management of treatment-related side effects. Research published in the journal Science and across major cancer centers worldwide has shown that patients with higher gut microbial diversity can have significantly better outcomes on certain therapies — particularly immune checkpoint inhibitors. Remarkably, one landmark study found that the composition of gut bacteria could predict whether a melanoma patient would respond to immunotherapy before treatment even began. In this article, we explore the science behind the gut-cancer treatment connection in meaningful depth: the specific bacterial species involved, how dysbiosis undermines treatment efficacy, what emerging interventions like fecal microbiota transplantation offer, and concrete, evidence-based strategies patients and caregivers can discuss with their oncology teams today.
—
Semantic Glossary
Understanding the terminology in this field will help you navigate both this article and conversations with your care team.
> Gut Microbiome
> The collective community of trillions of microorganisms — including bacteria, fungi, viruses, and archaea — that live in the human digestive tract, particularly the large intestine. These organisms play critical roles in digestion, immune regulation, and even neurological signaling.
> Dysbiosis
> An imbalance in the composition or function of the gut microbiome, characterized by a reduction in microbial diversity and an overgrowth of potentially harmful organisms. Dysbiosis is commonly observed in cancer patients and can be worsened by treatments such as chemotherapy, radiation, and antibiotics.
> Immunotherapy
> A class of cancer treatments that harness or enhance the body’s own immune system to identify and destroy cancer cells. Common forms include immune checkpoint inhibitors (such as anti-PD-1 and anti-CTLA-4 drugs), CAR-T cell therapy, and cancer vaccines.
> Fecal Microbiota Transplantation (FMT)
> A clinical procedure in which stool from a healthy, screened donor is transferred into the gut of a recipient in order to restore healthy microbial diversity. FMT is being actively studied in oncology as a way to improve treatment response and reduce side effects.
> Tumor Microenvironment (TME)
> The complex ecosystem surrounding a tumor, consisting of cancer cells, immune cells, blood vessels, signaling molecules, and the extracellular matrix. The gut microbiome can influence the tumor microenvironment through systemic immune and metabolic signals.
> Mucositis
> Painful inflammation and ulceration of the mucous membranes lining the digestive tract, commonly caused by chemotherapy or radiation. It is one of the most debilitating treatment-related side effects and is closely linked to disruptions in the gut microbiome.
—
What Is the Gut Microbiome and Why Does It Matter for Cancer Patients?
The human gut is home to an estimated 38 trillion microorganisms, a number that rivals — and may even exceed — the total count of human cells in the body. This vast internal ecosystem, known as the gut microbiome, is not a passive bystander in human health. It actively participates in digestion, nutrient synthesis, immune education, hormonal signaling, and even the regulation of inflammation — all processes that have direct implications for cancer patients undergoing treatment.
For cancer patients specifically, the gut microbiome matters for several interconnected reasons:
- Immune system modulation: Approximately 70% of the immune system resides in and around the gut. The microbiome plays a central role in training immune cells to distinguish between foreign threats and healthy tissue — a distinction that is critically important during immunotherapy.
- Drug metabolism: Gut bacteria can chemically alter anti-cancer drugs before they are absorbed into systemic circulation, either activating prodrugs into their therapeutic forms or deactivating already-active compounds.
- Inflammation regulation: A diverse, balanced microbiome helps suppress chronic inflammation — a known driver of tumor progression and treatment resistance.
- Barrier function: The gut lining acts as a physical barrier against pathogens and toxins. Disruption of this barrier by cancer or its treatment can allow bacterial products to enter the bloodstream, triggering immune responses that interfere with therapy.
Certain bacterial genera — including Bifidobacterium, Faecalibacterium, Akkermansia, and Lactobacillus — have been repeatedly associated with positive treatment outcomes and better immune health. Others, including certain strains of Bacteroides and Fusobacterium nucleatum, have been linked to treatment resistance and poorer prognoses.
Understanding your microbiome is not yet standard oncology practice, but it is rapidly becoming an area of intense clinical research. CAC encourages patients to ask their oncology team about emerging microbiome-related studies and clinical trials.
—
The Gut-Immune System Connection: Why Microbiome Health Is Central to Cancer Care
The relationship between the gut and the immune system is one of the most studied — and consequential — axes in modern medicine. For cancer patients, this relationship is not merely academic. It directly determines how robustly the immune system can fight cancer cells, tolerate treatments, and recover from therapy-related damage.
The gut microbiome educates immune cells from birth, teaching them when to activate and when to stand down. This education occurs primarily through:
- Pattern recognition: Microbial-associated molecular patterns (MAMPs) interact with toll-like receptors on immune cells in the gut lining, calibrating immune sensitivity.
- Regulatory T-cell development: Beneficial gut bacteria, particularly Clostridia species, promote the development of regulatory T cells (Tregs) that prevent autoimmune overactivation — critically important during immunotherapy.
- Short-chain fatty acid (SCFA) production: Bacteria like Faecalibacterium prausnitzii ferment dietary fiber to produce SCFAs such as butyrate, which have powerful anti-inflammatory and immune-regulating effects.
- Cytokine signaling: The gut microbiome influences the production of key immune signaling molecules, including interleukins and interferons, which shape the anti-tumor immune response.
When this gut-immune axis is disrupted — through dysbiosis, antibiotic exposure, or treatment side effects — the consequences for cancer patients can be significant:
- Reduced efficacy of immune checkpoint inhibitors
- Increased risk of immune-related adverse events (irAEs)
- Impaired recovery of white blood cell counts after chemotherapy
- Greater susceptibility to opportunistic infections
Critically, research has shown that the gut microbiome’s influence on immunity extends beyond the gut itself. Through systemic circulation of metabolites, immune cells educated in the gut travel to distant sites — including the tumor microenvironment — where they can either suppress or promote anti-tumor activity.
This is why maintaining gut microbiome health is not just a digestive concern — it is a core component of effective cancer treatment.
—
How Gut Bacteria Directly Influence Chemotherapy Drug Metabolism and Efficacy
One of the most compelling — and least widely understood — discoveries in oncology over the past decade is that gut bacteria can physically alter the behavior of chemotherapy drugs inside the body. This occurs through a series of well-documented mechanisms that researchers are only beginning to fully map.
Key Mechanisms of Microbiome-Chemotherapy Interaction
- Drug activation (bioactivation): Some chemotherapy drugs are administered as inactive prodrugs that require enzymatic conversion to become therapeutically active. Gut bacteria express enzymes — including beta-glucuronidases and azoreductases — capable of performing these conversions. An imbalanced microbiome can impair this process, reducing effective drug concentrations.
- Drug inactivation: Conversely, certain bacterial enzymes can deactivate chemotherapy drugs prematurely. The drug gemcitabine, used in pancreatic cancer, has been shown in preclinical research to be inactivated by bacteria of the Gammaproteobacteria class that colonize tumors — effectively rendering treatment less effective before drugs reach cancer cells.
- Alteration of intestinal permeability: Dysbiosis increases gut permeability (“leaky gut”), which alters how drugs are absorbed across the intestinal wall and distributed systemically.
- Immune priming for drug response: Some bacteria appear to prime immune cells to assist in the cytotoxic (cancer-killing) effects of certain drugs. Cyclophosphamide, for example, has been shown to work partly by inducing bacterial translocation from the gut to lymph nodes, where bacteria stimulate anti-tumor T-cell responses.
Clinical Evidence
Research published in Science demonstrated that Fusobacterium nucleatum — a bacterium associated with colorectal cancer — promotes resistance to fluorouracil (5-FU) chemotherapy by activating autophagy pathways within tumor cells, helping cancer cells survive drug exposure.
Additionally, studies in patients with pancreatic ductal adenocarcinoma found that intratumoral bacteria significantly modulated drug metabolism, suggesting the tumor’s own microbial residents — not just those in the gut — play a role in treatment resistance.
The practical implication: A patient’s gut microbial profile may be as relevant to chemotherapy dosing and regimen selection as their genetic tumor profile. This is an active and rapidly evolving area of precision oncology. Patients interested in learning more about how the microbiome may influence their specific treatment protocol should discuss this with their oncologist or seek out clinical trials at major cancer centers.
—
Microbiome Diversity and Immunotherapy Response Rates: What the Research Shows
Perhaps nowhere is the microbiome’s influence on cancer treatment more dramatic than in the field of immunotherapy. Multiple landmark studies across several cancer types — including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and bladder cancer — have found a striking association between gut microbial diversity and immunotherapy response rates.
What the Research Demonstrates
- A 2018 study published in Science by Gopalakrishnan et al. found that melanoma patients who responded to anti-PD-1 therapy (pembrolizumab or nivolumab) had significantly higher gut microbial diversity than non-responders. Responders showed enrichment of Faecalibacterium prausnitzii, Ruminococcaceae, and other butyrate-producing bacteria.
- A companion study by Routy et al., also published in Science in 2018, found that cancer patients (with NSCLC, renal cell carcinoma, and bladder cancer) who had taken antibiotics before or shortly after starting anti-PD-1 therapy had significantly shorter progression-free survival and overall survival — findings attributed to antibiotic-induced microbiome disruption.
- Research at MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy has since validated these findings in prospective cohort studies, confirming that the ratio of favorable to unfavorable bacteria can predict immunotherapy response.
Which Bacteria Are Associated With Better Outcomes?
- Associated with improved immunotherapy response: Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, Ruminococcaceae species
- Associated with poorer immunotherapy response: Bacteroidales order members, Prevotella copri, reduced Lachnospiraceae levels
The Mechanism
These bacteria appear to enhance immunotherapy efficacy by:
- Boosting CD8+ T-cell infiltration into tumors
- Reducing immunosuppressive Tregs within the tumor microenvironment
- Enhancing dendritic cell maturation, which improves antigen presentation to T cells
- Producing SCFAs that systemically modulate immune cell function
The implications are profound: a patient’s gut microbiome before treatment begins may be one of the most important — and modifiable — predictors of immunotherapy success.
—
How Cancer Treatments Like Antibiotics and Radiation Disrupt the Gut Microbiome
While cancer treatments are designed to eliminate or contain cancer, many have the unintended consequence of significantly damaging the gut microbiome. Understanding these disruptions is essential for oncology teams and patients alike.
Antibiotic Use in Cancer Patients
Cancer patients frequently require antibiotics to manage infections related to immunosuppression. However, antibiotics — particularly broad-spectrum varieties — can devastate microbial diversity with effects that persist for months to years after treatment ends.
- Antibiotics reduce the abundance of beneficial bacteria, including Bifidobacterium, Lactobacillus, and Faecalibacterium
- They create ecological niches that allow pathogenic organisms like Clostridioides difficile to flourish
- Multiple retrospective studies have linked antibiotic use during immunotherapy to reduced overall survival across several cancer types
Radiation Therapy
Radiation to the abdomen or pelvis directly damages the intestinal mucosa and the microbial communities it supports:
- Radiation-induced dysbiosis reduces microbial diversity and disrupts key fermentation pathways
- Patients undergoing pelvic radiation for gynecological, colorectal, or prostate cancers are particularly vulnerable
- Changes in the microbiome following radiation can persist long after treatment, contributing to chronic gastrointestinal complications
Chemotherapy
Beyond its direct cytotoxic effects on cancer cells, chemotherapy:
- Damages rapidly dividing intestinal epithelial cells, disrupting the physical environment bacteria inhabit
- Reduces immune surveillance in the gut, allowing overgrowth of pathogenic species
- Alters gut motility, transit time, and pH — all factors that shape microbial composition
The key takeaway: The very treatments used to fight cancer can compromise the gut ecosystem that supports treatment response. This creates a critical rationale for proactive microbiome support strategies before, during, and after treatment.
—
Gut Dysbiosis and Treatment Side Effects: From Mucositis to Immunosuppression
Gut dysbiosis is not merely a laboratory finding — it has real, measurable consequences for cancer patients experiencing some of the most challenging side effects of their treatments.
Mucositis
Mucositis is one of the most painful and functionally debilitating side effects of chemotherapy and radiation. Dysbiosis worsens mucositis through several pathways:
- Reduced barrier integrity allows bacteria to translocate across the gut lining, triggering local and systemic inflammation
- Loss of butyrate-producing bacteria impairs the fuel supply to colonocytes (cells lining the colon), accelerating mucosal breakdown
- Overgrowth of pathogenic organisms further damages inflamed mucosa
Studies show that patients with lower pre-treatment microbial diversity experience more severe mucositis and recover more slowly.
Chemotherapy-Induced Diarrhea and Nausea
- Dysbiosis disrupts normal gut motility and water/electrolyte absorption
- Loss of Lactobacillus and Bifidobacterium species reduces protection against gut pathogens
- Altered bile acid metabolism (heavily microbiome-dependent) contributes to osmotic diarrhea
Immunosuppression and Infection Risk
- A disrupted microbiome provides less competitive resistance against pathogens, increasing the risk of hospital-acquired infections
- Clostridioides difficile infection — a dangerous complication in cancer patients — is strongly linked to antibiotic-induced dysbiosis
- Systemic translocation of bacterial products (lipopolysaccharides) through a leaky gut activates inflammatory cascades that compound chemotherapy toxicity
Fatigue and Cognitive Effects
Emerging research connects gut dysbiosis to cancer-related fatigue through the gut-brain axis — a bidirectional communication network involving the vagus nerve, immune signaling, and microbial metabolite production. Disruption of this axis may contribute to the neurological fog and exhaustion many patients experience during treatment.
CAC recognizes that these side effects profoundly affect quality of life. Supporting gut health during treatment is not a luxury — it is part of comprehensive cancer care.
—
Fecal Microbiota Transplantation (FMT) as a Strategy to Enhance Cancer Treatment
Fecal Microbiota Transplantation (FMT) — the transfer of stool from a healthy donor into a patient’s gut — has been FDA-approved for recurrent Clostridioides difficile infection and is now being actively investigated as a strategy to improve cancer treatment outcomes.
The Rationale for FMT in Oncology
If a favorable gut microbiome predicts better immunotherapy response, then transplanting that favorable microbiome into a non-responder is a logical therapeutic strategy. This is exactly what researchers are now testing.
Key Clinical Trials and Findings
- Breakthrough results (2021, Science): A study by Baruch et al. at Sheba Medical Center conducted FMT from patients who had previously responded to anti-PD-1 therapy into patients with advanced melanoma who were non-responders. Following FMT plus reinstatement of anti-PD-1 therapy, 3 out of 10 non-responders achieved clinical responses — a remarkable finding given that these patients had already failed immunotherapy.
- A parallel study by Davar et al. at the University of Pittsburgh, published simultaneously in Science, showed similar results — FMT from responders enabled some non-responders to achieve anti-tumor responses with anti-PD-1 therapy.
- Ongoing trials are evaluating FMT in colorectal cancer, hematologic malignancies, and patients undergoing hematopoietic stem cell transplantation.
Considerations and Cautions
- FMT in immunocompromised cancer patients carries meaningful risks, including the potential transmission of pathogens. Two immunocompromised patients died in 2019 following FMT with donor stool containing drug-resistant bacteria.
- Current FMT oncology protocols involve rigorous donor screening and are conducted in clinical trial settings only.
- FMT is not a standard-of-care intervention for cancer patients outside of clinical trials at this time.
FMT represents one of the most promising frontiers in oncology microbiome research. Patients interested in these trials can ask their oncologist or explore listings at clinicaltrials.gov.
—
The Role of Diet in Shaping the Gut Microbiome During Cancer Therapy
Diet is the single most powerful modifiable factor influencing the gut microbiome — and for cancer patients navigating treatment, thoughtful nutritional choices can meaningfully support both microbial health and treatment tolerance.
Dietary Patterns That Support Microbiome Diversity
- High-fiber diets: Dietary fiber — found in fruits, vegetables, legumes, and whole grains — feeds beneficial bacteria and promotes SCFA production. Research published in Science found that melanoma patients eating higher-fiber diets had better responses to anti-PD-1 immunotherapy and richer microbiome diversity.
- Fermented foods: Yogurt, kefir, kimchi, sauerkraut, and miso naturally introduce live microorganisms into the gut. A Stanford University study (2021, Cell) found that a high-fermented food diet significantly increased microbiome diversity and reduced markers of inflammation.
- Mediterranean-style eating: Associated with high microbial diversity, this pattern emphasizes vegetables, legumes, whole grains, nuts, olive oil, and lean proteins.
- Polyphenol-rich foods: Berries, green tea, dark chocolate, and colorful vegetables contain polyphenols that selectively feed beneficial bacteria.
Dietary Patterns That Harm the Microbiome
- Highly processed foods and refined sugars reduce microbial diversity and feed pathogenic organisms
- Red and processed meats are associated with increased Bacteroidetes linked to unfavorable cancer outcomes
- Excessive alcohol disrupts gut barrier function and depletes beneficial microbes
Important Nuance for Cancer Patients
It is critical to acknowledge that cancer treatment often makes healthy eating extremely difficult. Nausea, mucositis, taste changes, fatigue, and appetite loss are real barriers. The goal is not perfection — it is making supportive food choices as often as safely possible.
CAC strongly recommends that patients work with an oncology-registered dietitian who can provide personalized guidance during treatment.
—
Probiotics, Prebiotics, and Synbiotics: Evidence-Based Use in Oncology Settings
The question patients most frequently ask regarding gut health during cancer treatment is: “Should I take probiotics?” The honest, evidence-based answer is: it depends — and always discuss with your oncologist first.
Definitions
- Probiotics: Live microorganisms that confer health benefits when consumed in adequate amounts. Common strains include Lactobacillus rhamnosus, Bifidobacterium longum, and Saccharomyces boulardii.
- Prebiotics: Non-digestible food ingredients (typically fibers) that selectively feed beneficial bacteria. Examples include inulin, fructooligosaccharides (FOS), and resistant starch.
- Synbiotics: Products that combine probiotics and prebiotics, intended to synergistically support gut health.
What the Evidence Shows
Potential benefits:
- Reduction of chemotherapy-induced diarrhea: Multiple randomized controlled trials have shown that Lactobacillus rhamnosus GG can significantly reduce the severity of chemotherapy-related diarrhea, particularly in colorectal cancer patients receiving irinotecan-based regimens.
- Reduction of antibiotic-associated diarrhea: Saccharomyces boulardii has reasonable evidence for reducing antibiotic-associated gut complications.
- Mucositis reduction: Some small trials suggest probiotics may reduce the incidence and severity of oral and intestinal mucositis.
Important cautions:
- Immunocompromised patients face real risks. Case reports exist of probiotic bacteremia (bacteria entering the bloodstream) in severely immunocompromised cancer patients. Probiotics are generally not recommended during periods of profound neutropenia without oncologist approval.
- Probiotics may interfere with certain immunotherapies by altering immune signaling in ways that reduce anti-tumor immune activation. A 2019 study found that commercial probiotic use was associated with lower microbial diversity and reduced immunotherapy response in melanoma patients.
- Not all probiotics are equivalent. Strain specificity matters enormously — a probiotic effective for diarrhea prevention may have no benefit (or potential harm) for immunotherapy augmentation.
The bottom line: Probiotics are not universally beneficial for cancer patients and should never be taken without oncologist review. However, prebiotic-rich whole foods are generally safe and supportive for most patients who can tolerate them.
—
Future Directions: Microbiome-Based Biomarkers and Personalized Cancer Treatment
The science of the gut microbiome and cancer is advancing at a remarkable pace. While much of today’s knowledge is still translating from research settings to clinical practice, the trajectory is clear: the microbiome will become an integral component of personalized oncology care.
Microbiome as a Predictive Biomarker
- Researchers are actively developing microbiome-based signatures that can predict, before treatment begins, which patients are likely to respond to specific therapies
- Companies including Seres Therapeutics, Vedanta Biosciences, and Enterome are developing microbiome-based products specifically for oncology
- Multi-center trials are validating microbiome profiling using 16S rRNA sequencing and shotgun metagenomics as tools to stratify patients into treatment protocols
Live Biotherapeutic Products (LBPs)
Rather than using broad-spectrum probiotics, researchers are developing defined consortia of specific bacterial strains targeted to produce particular immune effects. These LBPs represent the next generation of microbiome medicine:
- SER-401 (Seres Therapeutics): A defined microbiome product being studied in combination with pembrolizumab in melanoma
- VE800 (Vedanta Biosciences): Eleven defined strains designed to enhance anti-tumor immune response in combination with anti-PD-1 therapy
Microbiome Sequencing in Clinical Practice
- Tests that analyze gut microbial composition (such as Viome, Genova Diagnostics, and research-grade metagenomics) are not yet standard oncology tools
- However, academic cancer centers are increasingly incorporating microbiome data collection into clinical trial protocols
- Patients can ask their oncology team whether microbiome profiling is available as part of any current trial they may be eligible for
Integration with the Tumor Microenvironment
Future precision oncology will likely model the interaction between a patient’s germline genetics, tumor genomics, tumor microenvironment composition, and gut microbiome profile to generate truly individualized treatment recommendations.
Courage Against Cancer will continue to follow this science and update our resources as clinical evidence evolves. The microbiome may be one of the most important levers we have for improving cancer treatment outcomes in the coming decade.
—
Frequently Asked Questions
—
Can an unhealthy gut microbiome make chemotherapy less effective?
Yes, research suggests it can. Gut bacteria directly influence how chemotherapy drugs are metabolized, absorbed, and activated in the body. An imbalanced microbiome may deactivate certain drugs, impair immune-assisted drug action, or promote tumor survival pathways. This is an active area of oncology research, and patients should discuss microbiome health with their care team.
—
Which specific gut bacteria are associated with better immunotherapy outcomes?
Studies have most consistently linked Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and members of the Ruminococcaceae family to improved immunotherapy response rates. These bacteria appear to enhance T-cell activity, reduce tumor-associated immunosuppression, and support the systemic anti-tumor immune response through metabolite production.
—
How quickly does the gut microbiome change during cancer treatment?
The gut microbiome can shift measurably within days of starting chemotherapy or antibiotics. Significant reductions in microbial diversity can occur within the first cycle of chemotherapy. Recovery varies widely — some disruptions resolve within weeks, while others may persist for months or even years, particularly following bone marrow transplantation or prolonged antibiotic use.
—
Do antibiotics taken during cancer treatment reduce survival outcomes?
Retrospective studies suggest that antibiotic use — particularly broad-spectrum antibiotics administered within a few weeks before or after starting immunotherapy — is associated with shorter progression-free and overall survival in several cancer types, including lung, renal, and bladder cancers. However, antibiotics are often medically necessary. Patients should not avoid necessary antibiotics; rather, oncologists should weigh timing and antibiotic selection carefully.
—
Is fecal microbiota transplantation safe for cancer patients receiving treatment?
FMT carries meaningful risks in immunocompromised patients, including potential transmission of pathogens. While FMT is being studied in oncology clinical trials with rigorous safety protocols, it is not a standard-of-care intervention for cancer patients outside of these controlled settings. Patients should only pursue FMT through established clinical trial programs with proper donor screening.
—
What foods support a healthy gut microbiome during chemotherapy?
Foods that support microbiome diversity include high-fiber vegetables and legumes, fermented foods (when tolerated and approved by your care team), berries and polyphenol-rich fruits, whole grains, nuts, seeds, and olive oil. However, treatment side effects may limit food tolerability. Working with an oncology-trained registered dietitian is the most effective way to personalize dietary support during chemotherapy.
—
Can probiotics reduce chemotherapy-induced diarrhea and nausea?
Some evidence supports specific probiotic strains — particularly Lactobacillus rhamnosus GG and Saccharomyces boulardii — for reducing chemotherapy-related diarrhea. Evidence for nausea reduction is more limited. Critically, probiotics can pose risks in immunocompromised patients and may interfere with certain immunotherapies. Always consult your oncologist before taking any probiotic supplement during cancer treatment.
—
Does the gut microbiome affect the risk of cancer recurrence after treatment?
Emerging evidence suggests it may. Studies in colorectal cancer have found that Fusobacterium nucleatum — a bacterium linked to treatment resistance — can persist in metastatic sites after treatment and may contribute to disease recurrence. Research in this area is preliminary but actively growing. Maintaining microbiome health during remission may be an important, though not yet proven, factor in long-term cancer control.
—
Are there microbiome tests cancer patients should ask their oncologist about?
Commercial microbiome tests (such as those offered by Viome or diagnostic labs) are not currently validated for use in standard oncology decision-making. However, several major cancer centers and clinical trials are incorporating research-grade microbiome sequencing. Patients should ask whether any clinical trial they’re enrolled in or eligible for includes microbiome profiling — this is where the most clinically meaningful data is currently being generated.
—
How does the microbiome differ between cancer patients who respond well to treatment and those who do not?
Responders to immunotherapy consistently show higher overall microbial diversity, greater abundance of butyrate-producing bacteria, stronger representation of Ruminococcaceae and Faecalibacterium species, and a healthier gut epithelial barrier. Non-responders tend to have lower diversity, higher proportions of bacteria from the Bacteroidales order, and a microbiome profile associated with systemic inflammation and immune suppression.
—
Conclusion
The gut microbiome is no longer a peripheral consideration in oncology — it is emerging as a central, modifiable factor in how cancer patients respond to chemotherapy, radiation, and immunotherapy. From the bacterial metabolites that activate or deactivate drugs, to the microbial signals that shape immune responses in and around tumors, the science is clear: gut health matters profoundly in cancer care.
At Courage Against Cancer (CAC), we believe that knowledge is power. Understanding the connection between your gut microbiome and cancer treatment outcomes gives you and your care team one more tool — one more opportunity to optimize your treatment experience and improve your quality of life. This field is evolving rapidly, and there is genuine hope in the research emerging from cancer centers around the world.
You are not alone on this journey. CAC is here to translate complex science into actionable, compassionate guidance — and we are committed to updating our resources as this important science continues to grow. Please share this article with your care team, ask questions, and take an active role in every aspect of your cancer care.
Together, we face cancer with courage.
—
Medical Disclaimer
> This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions. Courage Against Cancer does not diagnose, treat, cure, or prevent any disease.
—
Sources
1. Gopalakrishnan, V., Spencer, C.N., Nezi, L., et al. (2018). “Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients.” Science, 359(6371), 97–103. https://doi.org/10.1126/science.aan4236
2. Routy, B., Le Chatelier, E., Derosa, L., et al. (2018). “
Discover more from Courage Against Cancer
Subscribe to get the latest posts sent to your email.